Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer.
Malamut was most recently Senior VP of Global Clinical Development and Head of Pain, Oncology, Neuropsychiatry and NTEs at Teva Pharmaceuticals.
Avanir President and CEO Rohan Palekar said, “Richard will play an important role at Avanir as we continue our commitment to develop innovative treatments to address the unmet medical needs of people with CNS disorders. His background in all stages of product development, from conducting feasibility studies to serving as moderator for FDA Advisory Committee meetings, as well as his expertise in neurology, will be invaluable as we continue our focus on R&D and building our pipeline.”
Read the Avanir Pharmaceuticals press release.
